My video commentary on The Negative Article about Alexza 12/5/12, written by Jason Napodano, CFA which can be found at http://propthink.com/alexza-meaningfully-overvalued-following-its-latest-rally/4120
Tag: stocks
Voce Capital Management Goes Hardball With Proxy Fight Against Obagi Board
Another chapter has been written on the nearly year long effort by Voce Capital management to get Obagi Medical Products (OMPI) sold, when on Monday, 12/3/12, Voce made public another letter sent to the Obagi Board of Directors (BOD) In…
XenoPort Catalyst DD – December 31st
Catalyst: XenoPort conducted an End-of-Phase 2 meeting with the FDA in which it received feedback that a proposed development program for XP21279, a novel prodrug of levodopa, could support a potential New Drug Application (NDA) submission under Section 505(b)(2) of…
MEI Pharma (MEIP): Significant Catalyst Trade Potential
MEI Pharma, Inc. (MEIP), will be presenting data on Pracinostat, in combination with azacitidine in patients with advanced myelodysplastic syndrome (MDS) at a poster presentation at the American Society of Hematology Annual Meeting on December 10, 2012. An abstract of…
11/30/12 Catalyst Trade And Speculation Investment List
Alexza Pharma (NASDAQ: ALXA) Alexza engages in the research, development, and commercialization of novel proprietary products for the acute treatment of central nervous system conditions worldwide. Its product candidates are based on a proprietary technology, the Staccato system, which vaporizes…
Huge Swing Trade Potential For Alexza Pharma With Two December Catalysts
Alexza Pharma (NASDAQ: ALXA) engages in the research, development, and commercialization of novel proprietary products for the acute treatment of central nervous system conditions. Its product candidates are based on a proprietary technology, the Staccato system, which vaporizes an excipient-free…
Near Term Catalysts For Anacor Pharma Should Make For Nice Upside Gain
Trading biophama companies before a catalyst event, if done correctly, can be a very profitable proposition. Some traders and investors who enjoy bringing more risk into play often times will hold through the actual catalyst event. While this does bring…
November 10 Biotech Update
This past week was a bit rough on the overall markets as on Tuesday, the markets seemed to bet on a Romney win, only to sell off the next day on news of an Obama win. The good news for…
Speculation In The Patent Litigation Segment: Seeking Out The Next Big Stock Movers.
There has been a lot of buzz lately about Vringo’s (VRNG) patent infringement lawsuit against Google (GOOG). Google’s ad placement system and its possible infringement of the Lang/Kosak Relevancy Filtering Technology with patents 420 and 664 are being called into…
